Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35940512)

  • 1. Effect of exercise on tumor markers - Is exercise anti-tumorigenic in humans?: A scoping review of preliminary clinical investigations.
    Kang DW; Barnes O; Vander Heiden MG; Dieli-Conwright CM
    Crit Rev Oncol Hematol; 2022 Oct; 178():103779. PubMed ID: 35940512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor markers of breast cancer].
    Sławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts.
    Zhao Y; Verselis SJ; Klar N; Sadowsky NL; Kaelin CM; Smith B; Foretova L; Li FP
    J Clin Oncol; 2001 Mar; 19(5):1462-7. PubMed ID: 11230492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1998 Feb; 16(2):793-5. PubMed ID: 9469371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.
    Bast RC; Ravdin P; Hayes DF; Bates S; Fritsche H; Jessup JM; Kemeny N; Locker GY; Mennel RG; Somerfield MR;
    J Clin Oncol; 2001 Mar; 19(6):1865-78. PubMed ID: 11251019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum (circulating) tumor markers for breast cancer.
    Hayes DF
    Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study.
    Baselice S; Castaldo R; Giannatiempo R; Casaretta G; Franzese M; Salvatore M; Mirabelli P
    Cancer Control; 2021; 28():10732748211048612. PubMed ID: 34620015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control.
    Staab HJ; Ahlemann LM; Anderer FA; Zwirner M; Schindler AE
    Cancer Detect Prev; 1985; 8(1-2):35-45. PubMed ID: 4064050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.
    Duffy MJ; McDermott EW; Crown J
    Tumour Biol; 2018 May; 40(5):1010428318776169. PubMed ID: 29775157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Van Poznak C; Somerfield MR; Bast RC; Cristofanilli M; Goetz MP; Gonzalez-Angulo AM; Hicks DG; Hill EG; Liu MC; Lucas W; Mayer IA; Mennel RG; Symmans WF; Hayes DF; Harris LN
    J Clin Oncol; 2015 Aug; 33(24):2695-704. PubMed ID: 26195705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review.
    Laraib U; Sargazi S; Rahdar A; Khatami M; Pandey S
    Int J Biol Macromol; 2022 Jan; 195():356-383. PubMed ID: 34920057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer.
    Ayala de la Peña F; Ortiz-Muñoz B; Quintanar-Verdúguez T; Santotoribio JD; de la Cruz S; Trapé-Pujol J; Galve-Calvo E; Augé-Fradera JM; García-Gómez J; González-Hernández Á
    Clin Transl Oncol; 2021 Jul; 23(7):1272-1280. PubMed ID: 33550504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
    Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
    J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.